TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers. Our lead therapeutic product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. TTX-MC138 has recently completed a Phase 1a clinical trial.
Phase 2 · ActiveModality: oligonucleotide conjugated to iron oxide nanoparticle
Target miR-10b
Indications
Metastatic cancer (Phase 1a, patients continuing on trial)(Phase 1)
Colorectal cancer at high risk of recurrence after curative-intent therapy (Phase 2a)(Phase 2)
Catalysts
— Q3 2026
Status note Lead candidate: oligonucleotide conjugated to an iron oxide nanoparticle, administered by infusion, designed to inhibit the ability of metastatic tumor cells to survive. Phase 1a trial (commenced Q3 2024) ongoing with patients continuing. Phase 2a trial in colorectal cancer patients at high risk of recurrence initiated Q2 2026; initial enrollment expected Q3 2026.
Seviprotimut-L
Stage not disclosed · Active
Indications
Stage IIB and IIC melanoma micrometastases (potential combination with TTX-MC138)(Stage not disclosed)
Status note Additional pipeline cancer therapy candidate; company evaluating potential to augment its anti-cancer effects by combining with TTX-MC138 to address micrometastases in stage IIB/IIC melanoma. Phase not disclosed in the excerpts.
Partnerships Licensed from Unleash Immuno Oncolytics, Inc.
Indications
Cancer(Preclinical)
Status note Pre-clinical candidate program involving genetically-engineered adenoviruses to harness the immune system to fight cancer, licensed from Unleash Immuno Oncolytics.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
HER2-positive Breast Cancer; Metastatic Cancer; Metastatic Breast Cancer
—
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.